The tissue microenvironment in chronic lymphocytic leukemia (CLL) has an increasingly recognized role in disease progression, but the molecular mechanisms of cross talk between CLL cells and their microenvironment remain incompletely defined. Bone marrow stromal cells (BMSC) protect CLL cells from apoptosis in a contact-dependent fashion, and have been used for the identification of key pathways such as the CXCR4 --CXCL12 axis. To further dissect the molecular impact of BMSC on survival and the molecular activation signature of CLL cells, we co-cultured CLL cells with different BMSC. Gene expression profiling of CLL cells revealed that the lymphoid proto-oncogene TCL1 was among the top genes upregulated in CLL cells by BMSC. TCL1 mRNA and protein upregulation by BMSC was paralleled by decreases of TCL1-interacting FOS/JUN, and confirmed by qRT-PCR, immunoblotting, immunoprecipitations, and flow cytometry. Stroma mediated increases in TCL1 were also associated with decreased levels of TCL1-regulatory micro-RNAs (miR-29b, miR-181b, miR-34b). These findings demonstrate that the microenvironment has a proactive role in the regulation of the known signaling enhancer and pro-survival molecule TCL1 in CLL. This provides a further rationale for therapeutically targeting the cross talk between CLL and BMSC.
INTRODUCTION
Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is a lymphoproliferative disorder with a highly variable clinical course. CLL is characterized by the clonal expansion of mature, antigen-stimulated CD5 þ /CD23 þ B lymphocytes in peripheral blood, secondary lymphoid tissues and the bone marrow (BM). 1 CLL cells proliferate in the tissue compartments (BM, lymphatic tissues) in distinct areas called proliferation centers or pseudo-follicles, a hallmark finding in CLL histopathology. 2 CLL cell growth accounts for a daily turnover of approximately 0.1 --1% of the clone, as demonstrated by in vivo kinetics of cellincorporated deuterated water. 3 In the tissue compartments, CLL cells engage in complex cellular and molecular interactions with accessory cells, collectively referred to as the CLL microenvironment (reviewed in Burger et al. 4 ). For example, in the lymphatic tissues, CLL cells interact with T cells 5 and CD68 þ , monocytederived nurse-like cells (NLC), 6 and display signs of B-cell antigen receptor (BCR) activation, 7, 8 suggesting that CLL cell proliferation is BCR-and T-cell driven.
To model and dissect these complex cellular and molecular interactions in vitro, we previously performed gene expression (GE) analysis of CLL cells in the context of co-culture with different stromal cells to detect stroma-induced GE changes. 7 There, we utilized NLC, a model resembling CLL cell exposure to the lymphatic tissue microenvironment. NLC-induced GE changes are remarkably similar to GE profiles of CLL cells isolated from CLL lymph nodes in vivo, 8 emphasizing the validity of this approach. To expand on these findings and to test whether stroma cell exposure induces modulation of key survival genes with largely unknown mode of regulation in CLL, such as the T-cell leukemia/ lymphoma 1 (TCL1) proto-oncogene, we analyzed GE changes in purified CLL cells during co-culture with mesenchymal bone marrow stromal cells (BMSC). BMSC are known to profoundly influence the development and progression of various cancers. 9 Co-culture of CLL cells with BMSC results in the rapid, spontaneous migration of a fraction of CLL cells beneath and underneath the BMSC (pseudoemperipolesis) 10 and protects CLL cells from spontaneous or drug-induced apoptosis. 6, 11, 12 The prototypic TCL1 gene family member TCL1 encodes for a 114 amino acid, 14 kDa proto-oncogene that initially was identified as a target of chromosomal inversions and translocations at the 14q32.1 chromosome breakpoint region in T-cell prolymphocytic leukemia. 13 TCL1 is differentially expressed during normal B-cell development, with robust expression levels from pre-B cells through peripheral naïve B cells, repression in germinal center B cells and silencing in post-germinal center memory B and plasma cells.
14 TCL1 functions as a co-activator of the prosurvival serine threonine kinase AKT (PKB) by interacting with its pleckstrin homology domain. 15, 16 Besides acting as a positive modulator of AKT kinase activity, TCL1 also enhances NF-kB activity and inhibits activator protein 1 (AP-1) transcription factor activity. 17 In CLL, TCL1 is differentially expressed, and higher TCL1 protein levels correlate with more aggressive clinical features. 18 Upon BCR engagement, TCL1 and AKT co-recruit to BCR membrane-activation complexes, with TCL1 expression levels predicting BCR signaling and growth responses. 19 However, chromosomal aberrations that constitutively activate TCL1, as seen in T-cell prolymphocytic leukemia, have not been identified in CLL, 20 and the mechanism(s) regulating TCL1 expression in CLL remain largely unknown except for reports on posttranscriptional TCL1 regulation by micro (mi)-RNAs. 21 The association of higher TCL1 levels in those CLL with the del(11q23) aberration 19 recently has been explained by concurrent losses of miRNA-34b/miRNA-34c. 22 In the presented study, we detected a robust increase in the expression of TCL1 along with decreases of the FOS/JUN AP-1 family members as one of the most significant and consistent molecular events after CLL-BMSC co-culture. Confirmatory experiments of these microarray-based findings at the RNA and protein level indicated that especially strong cell --cell contacts rather than humoral factors lead to this modulation. This is also accompanied by TCL1-complex trapping of certain FOS/JUN proteins of the AP-1 family. Parallel down-modulation of TCL1-regulatory mi-RNA's may in part explain the underlying mechanism of TCL1 induction.
MATERIALS AND METHODS

Cell purification and culture conditions
After informed consent was obtained in accordance with the Declaration of Helsinki on the Institutional Review Board-approved protocols of both participating institutions, peripheral blood samples were collected from consecutive untreated patients fulfilling the clinical and immunophenotypic diagnostic criteria for CLL at the Leukemia Department at MD Anderson Cancer Center, Houston and Cologne University. Patient characteristics are summarized in Supplementary Table S1 . To isolate peripheral blood CLL B cells before culture or RNA isolation, CLL PBMC after nylon mesh pre-filtration were purified with CD19 MicroBeads by the MACS technology (Miltenyi Biotec, Bergisch Gladbach, Germany), with subsequent total RNA extraction performed with the PureLink Micro-to-Midi Total RNA Purification System (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. For patients #28 --34 (Supplementary Table S1 ), CLL cells were isolated by Ficoll Paque Plus (GE Healthcare, Waukesha, MI, USA) centrifugation after negative selection (RosetteSep human B-cell enrichment cocktail; StemCell Technologies, Cologne, Germany).
Purified CLL cells were cultured alone, in medium supplemented with interleukin (IL)-4 (10 ng/ml, R&D Systems, Minneapolis, MN, USA) in conditioned medium as 2-days old supernatants of the respective feeder BMSC or in CLL-BMSC co-cultures. For co-cultures with BMSC, CD19 purified CLL PBMC were suspended in RPMI 1640 culture medium (for KUSA-H1) supplemented with 10% FBS, L-glutamine and penicillin --streptomycin or in alpha-MEM (for StromaNKtert) added by 12.5% FBS, 12.5% human serum, 1 mM hydrocortisone and 100 mM mercaptoethanol. At a concentration of 10 7 per ml in 20 ml, CLL cells were incubated in 75 cm The bone marrow stroma cell (BMSC) lines KUSA-H1 (murine) and StromaNKtert (human) 23 were purchased from RIKEN (Ibaraki, Japan) and cultured as described. 12 CLL cell viability was studied by the analysis of mitochondrial transmembrane potential using 3,3 0 -dihexyloxacarbocyanine iodide (DioC6; Molecular Probes, Life Technologies, Grand Island, NY, USA) and by cell membrane permeability to propidium iodide (SigmaAldrich, St Louis, MO, USA), and measured by FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Studies of CLL gene expression profiles under BMSC co-culture
In order to analyze gene expression profile changes in CLL cells during co-culture with KUSA-H1 and StromaNKTert BMSC cells, CLL cells were harvested at 2 and 7 days of co-incubation. Total RNA was isolated from CLL cells after Ficoll separation and subsequent purification with CD19 MicroBeads, as described. 7 A baseline (day 0) RNA sample was also prepared before the start of BMSC co-cultures. Furthermore, RNA from BMSC co-cultured CLL cells from the same patient was isolated at 2 and 7 days. The RNA obtained was quantified using a NanoDrop 1000 spectrophotometer (Fisher Scientific, Pittsburgh, PA, USA). Gene expression profiles were determined using HG U133 plus 2.0 oligonucleotide arrays from Affymetrix (Santa Clara, CA, USA), as described. 7 Flow cytometry, western blotting, immunoprecipitations (IPs) and quantitative real time RT-PCR The expression of TCL1 in CLL cells was analyzed by cytoplasmatic staining, and flow cytometry analysis in 14 CLL samples before and after co-culture with StromaNKtert BMSC, respectively, on day 3 and day 7, using anti-CD19 allophycocyanin (APC; BD Biosciences, San Jose, CA, USA), anti-TCL1 phycoerythrin (PE) and APC (both clone 1 --21, eBioscience, San Diego, CA, USA) or isotype control IgG 2 b (Sigma-Aldrich) and the BD Cytoxic/ Cytoperm kit (BD Biosciences). In four additional cases, we performed TCL1-flow cytometry on fractionated harvests according to the presence and strength of cellular (CLL-BMSC) adhesion in comparison to conditions of sole culture media and conditioned media of the respective BMSC line. In detail, CLL cells were harvested from co-cultures at day 2 and 7 by first removing the culture supernatant (fraction 1, containing spontaneously 'suspended' cells), later indirect re-application of media and gently rinsing 'loosely adherent' cells (fraction 2), and finally washing 'strongly attached' cells (fraction 3) after vigorously tapping the culture flask for 10 times.
For immunoblot assays in 11 CLL according to published protocols, 19 we used the following primary antibodies: anti-phospho(p)AKT (Ser473) clone D9E (Cell Signaling Technology/New England Biolabs, Frankfurt, Germany), anti-MCL1, anti-GAPDH, anti-JUND, anti-FOSB, anti-Akt1/2 (all Santa Cruz Biotechnology, Heidelberg, Germany), anti-TCL1 18 as well as c-FOS (Cell Signaling Technology) and anti-b-Actin (Sigma-Aldrich). IP analysis of interacting proteins in primary CLL cells (seven cases) was performed as described previously. 19 Protein lysates were immunoprecipitated either with mouse IgG isotype antibody (Sigma-Aldrich) or mouse anti-TCL1 antibody (clone 1 --21). 18, 19 Isolated protein complexes were separated by denaturing SDS-PAGE, and TCL1-interacting partners were detected by subsequent western blots using the following antibodies (same sources as above): rabbit anti-JUND, goat anti-FOSB, rabbit c-FOS and rabbit anti-AKT1/2. Incubations of PAGE-separated IP's with TCL1 as well as of the pre-IP lysates (input) with mouse anti-b-Actin served as controls. The input western blots controlled for the existence of BMSCinduced TCL1, c-FOS, FOSB and JUND regulation in the harvested condition. For quantitative real time RT-PCR, total RNA from CLL cells was extracted using the Trizol/chloroform method (Invitrogen, Karlsruhe, Germany). Then, quantitative real time PCR was performed using the LightCycler rapid thermal cycler (Roche Diagnostics, Mannheim, Germany) and Express SYBR Green qPCR SuperMix (Invitrogen, Karlsruhe, Germany) with the specific primers: TCL1A primers (forward---5 0 -GGAGAAGTTCGTG-TATTTGG-3 0 ; reverse---5 0 -CGCCGTCAATCTTGATG-3 0 ), miRNA forward primers were purchased commercially (Probe IDs: 3145, 3146, 2908; Invitrogen, Karlsruhe, Germany) and miRNA reverse primers were supplied as part of the cDNA synthesis kit (Invitrogen, Karlsruhe, Germany); and primers targeting the 7SL gene were used for normalization.
Data analysis and statistics
Results are shown as means plus/minus standard error of the mean (s.e.m.) or standard deviation (s.d.), as indicated. For comparisons of groups, the Student paired t-test was used. Analyses were performed using the GraphPad Prism 4 software for Macintosh (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
BMSC are superior to IL-4 in supporting CLL cell survival Figure 1a displays phase contrast photomicrographs of BMSC and CLL-BMSC co-cultures. Addition of IL-4, a potent, generally T-cellderived cytokine known to promote CLL cell survival, to culture medium in the absence of BMSC had only a modest effect on CLL cell viability in five analyzed samples (patients #17, 18, 19, 25, 27, see Supplementary Table S1 ) (Figure 1b) , causing an approximate 10--20% increase in CLL cell viability on days 2 and 7, respectively (mean ± s.e.m. viability: 52.8 ± 4.1%, Po0.05 and 57.3 ± 3.7%, Po0.01), when compared to CLL cells in medium alone (mean ±-s.e.m.: 40.0±3.6% and 37.7±3.6%). In comparison, co-culture with BMSC had a more robust effect on CLL cell viability. We found that the mean CLL cell viability in co-cultures with KUSA-H1 cells was significantly increased to 63.6±6.0% (Po0.01) on day 2 and to 93.3±2.3% (Po0.01) on day 7 (mean±s.e.m.). Similarly, StromaNKTert increased CLL cell viabilities to 87.4 ± 3.1% (Po0.01) on day 2 and to 97.9 ± 0.1% (Po0.01) on day 7 (mean ± s.e.m., Figure 1b ). These findings indicate that BMSC provide a more robust support of CLL cell viability than IL-4 alone.
Upregulation of TCL1 appears along with the reduction of FOS and JUN transcripts in CLL cells during BMSC co-culture We observed a relatively homogenous GE response across nine CLL cases (patients #1 --9, in Supplementary Table S1) during co-culture with the two different BMSC cell lines, murine KUSA-H1 and human StromaNKtert. Table 1 depicts GE changes in CLL cells in response to co-culture with StromaNKtert cells, displaying the top 10 genes that were most highly upregulated or downregulated after 7 days of co-culture with these BMSC. This was based on at least threefold upregulation in at least six of the paired specimens, and was representative for most of the genes for both time points (days 2 and 7) and both BMSC (StromaNKtert and KUSA-H1). The heat maps displayed in Figure 2 demonstrate the homogeneous TCL1 upregulation and FOS downregulation under each of these conditions. Among the genes that were most strongly upregulated under all conditions of BMSC co-culture are TCL1, CLLU1, a CLL-restricted gene of unknown function, and the toll-like receptors (TLR), TLR7 and TLR10. The most downregulated genes were the nuclear lamina proteins Lamin A/C (LMNA), the FOS gene family members FOS and FOSB. The proto-oncogenes JUN and JUND were also among the top 500 most strongly downregulated genes in all conditions. JUND was found more than threefold downregulated in seven of the nine cases (mean fold change À8.457), and JUN was found more than threefold downregulated in six of the nine cases (mean fold change À7.997). JUN and FOS family members can dimerize, thereby forming the transcription factor complex of AP-1, which is implicated as a master regulator of apoptosis, cell proliferation, differentiation, and transformation. 24 BMSC-induced TCL1 induction is confirmed by quantitative reverse transcription PCR (qRT-PCR) and shows early-onset kinetics When using TaqMan qRT-PCR assays to evaluate the accuracy of expression values from Affymetrix microarrays, we observed a close correlation between measurements obtained with the two platforms and using the two different BMSC lines in four CLL cases, as displayed in Figure 3a . The qRT-PCR data shown in Figure 3b depict the time course of stroma-induced TCL1 expression in five additional CLL, indicating that this occurs mainly between 8 and 48 h after the initiation of the co-cultures (Figure 3b ).
Flow cytometry confirms BMSC-induced TCL1 upregulation at the protein level Using mean fluorescence intensity ratios, we quantified TCL1 protein expression by flow cytometry. In accordance with our microarray and qRT-PCR data, we found in 14 (patients #10 --23, in Supplementary Table S1 ) analyzed cases a significant upregulation of TCL1 levels ( Figure 4 ) at day 7 of co-culture on StromaNKtert cells when compared to baseline (day 0).
Increases in TCL1 expression after CLL-BMSC co-culture are paralleled by enhanced AKT and MCL1 protein expression As TCL1 is a co-activator of the AKT oncoprotein and its downstream target MCL1 a central pre-survival executioner in CLL, we next explored AKT and MCL1 activation after BMSC coculture by immunoblotting. Figure 5a depicts western blots from four different CLL patients (patients #24 --27, in Supplementary  Table S1 ), probed with antibodies for TCL1, AKT, pAKT, MCL1, and GAPDH. We found the increases in TCL1 protein to be associated with robust increases of serine (Ser)473 phospho-activated (p)AKT, AKT isoforms 1 and 2, and MCL1 after BMSC co-culture.
Fractionated harvests of BMSC-CLL co-cultures indicate that direct cell --cell interactions favor BMSC-induced TCL1 upregulation In four additional cases (part of the seven cases analyzed for TCL1/ JUN/FOS coregulation and interaction, below), we harvested the CLL cells co-cultured with KUSA-H1 and StromaNKtert at days 2 and 7, and analyzed them for TCL1 in a manner that would allow separation according to the extent of the direct CLL-BMSC interaction (see Materials and Methods) into BMSC-adherent and supernatant cells. In addition to these fractions of CLL-BMSC adherence, we also analyzed CLL cells exposed only to the medium component of these BMSC lines (conditioned media). The Supplementary Figure S1 illustrates in two different cases (one for each BMSC line) that the BMSC-adherent CLL cell fraction displays the highest TCL1 levels, when compared to loosely adherent or non-adherent (supernatant) CLL cells. Moreover, TCL1 upregulation in CLL cells exposed to conditioned medium from BMSC was relatively lower, overall indicating that direct cell --cell interactions between CLL cells and BMSC provide the best conditions for increasing TCL1 levels.
The upregulation of TCL1 protein in CLL-BMSC cultures is associated with down-modulation of AP-1 proteins of the FOS/JUN family but their preservation in TCL1 complexes Although of variable magnitude and kinetics across cases, we show in seven additional samples (patients #28 --34 in Supplementary Table S1 ) by immunoblot that the BMSC-induced altered protein levels for TCL1 and the AP-1 transcriptional complex members FOS and JUN, are in concordance with the observed GE array data, flow cytometry data and PCR-confirmed changes (Figures 6a and b) . As TCL1 is reported to interact with certain AP-1 members, 17 we performed TCL1-IPs of harvests to assess the content of complexed FOS/JUN family members in the TCL1 protein isolates. Despite the observed down-modulation of overall protein levels of c-FOS, FOSB, and JUND, their net content of the TCL1-bound fraction does not seem to drop, but rather increase for some of them, such as c-FOS (Figure 6c ). This is less likely a result of the overall TCL1 increase, as the fraction of immunoprecipitated TCL1 remained constant.
BMSC co-culture promotes decreases in TCL1-regulatory miRNA's As the magnitude of the uniform BMSC-mediated induction of TCL1 mRNA was impressively high (up to approximately 100-fold), in eight additional CLL samples analyzed (patients #35 --42 in Supplementary Table S1 ) (Figure 7a) , we further investigated possible mechanisms that may contribute to the sustained elevation of TCL1 mRNA and protein. We therefore examined the levels of described negative regulators of TCL1, namely its 3 0 UTR targeting miRNA-29b, miRNA-181b and miRNA-34b, 21, 22 in the same samples by qRT-PCR. This analysis revealed decreased levels of these three miRNAs primarily at 7 days of BMSC (especially StromaNKtert) co-culture (Figure 7b) . In addition to the fact that the observed reduction in miRNA levels appeared preferentially at the later (day 7) time point and often after an initial increase at the early day 2 time point, these drops in miRNA expression were of lower magnitude and more heterogeneously distributed across cases than the induced increases in TCL1 mRNA levels. This heterogeneity did not correlate with the basal miRNA or TCL1 levels of the cases.
DISCUSSION
CLL is associated with high-level expression of the protooncogene TCL1. 18, 19 Experimental deregulation of human (transgenic) TCL1 in murine B cells causes B-cell proliferations resembling aggressive human CLL, 25 demonstrating that TCL1 overexpression is a causal event in the development of CLL. The event(s) responsible for deregulation of TCL1 in human CLL are, in the absence of detectable chromosomal aberrations involving its locus, 20 largely unknown. In previous in situ and in vitro studies, we demonstrate that TCL1 in CLL and in other B-cell tumors underlies dynamic (down)-regulations in strong association with (humoral) T-cell mediated factors. 14, 18 Here, we provide first experimental evidence that primarily cell --cell mediated signals from the stromal microenvironment induce TCL1 overexpression in CLL cells, along with repression of the TCL1 target molecules FOS and JUN, and TCL1-regulatory miRNA species.
Our data indicate that external signals from BMSC have an important role for the regulation of TCL1 in CLL. Interestingly, these changes were induced by murine and human BMSC, but not by monocyte-derived NLC, as previously reported by us. 7 This finding points towards mechanisms that are functional in BMSC---but not in NLC---cross talk with CLL cells, making some of the prominent pathways such as the CXCR4 --CXCL12 axis, B-cell activating factor of the tumor necrosis factor family (BAFF), a proliferation-inducing ligand (APRIL), 26 CD31, or plexin-B1 27 unlikely candidates for stroma-induced TCL1 over-expression. Moreover, in contrast to CLL-NLC co-cultures, where ZAP-70 expression by the CLL cells correlated with gene expression profile changes, 7 we did not find any significant correlation between CLL risk factors (ZAP-70, IGHV mutational status, CD38) and upregulation of TCL1 by BMSC, again suggesting that the mechanisms of activation and TCL1 induction by BMSC are different and distinct from those by NLC.
The importance of BMSC and the marrow microenvironment for protection of CLL and other leukemia cells from drug-induced apoptosis is increasingly recognized, based upon in vitro and in vivo studies published over the last decade (reviewed in Burger et al. 28 and Meads et al. 29 ). These studies defined the importance of BMSC 6, 11, 30, 31 for providing survival, growth and drug-resistance signals, which may explain why the marrow is a preferential site for minimal residual disease 32 and relapses even after extremely effective conventional treatments. 29 BMSC are known to protect CLL cells from apoptosis 6, 11 and represent an important stromal cell population in the CLL microenvironment, not only in the BM but also in the lymphatic tissues, 33 where aSMA þ mesenchymal stromal cells 33 represent lymphatic tissue counterparts of BMSC. BMSC regulate hematopoiesis by providing attachment sites and secreted or surface-bound growth factors that constitute the marrow microenvironment. 34 During B-cell development in the marrow, programmed cell death regulates B-cell homeostasis by diverting a large fraction of immature B cells into an apoptotic death pathway to eliminate functionless or potentially harmful cells. 35, 36 Critical factors for the survival of selected B cells are interactions with BMSC, 37 --39 expression of surface immunoglobulin molecules and expression of apoptosis-regulatory proteins, such as BCL2. 40 In patients with CLL, the marrow invariability is infiltrated with CLL cells, and the pattern and extent of marrow infiltration correlates with clinical stage and prognosis. 41, 42 Previous studies to model the in vivo marrow microenvironment employed co-culture assays with various BMSC of murine 6, 43 and human 11, 44 origins, and we recently demonstrated that murine and human BMSC do not significantly differ in their capacity to support CLL cell viability, protection from cytotoxic drugs and maintenance of antiapoptotic proteins, such as MCL1. 12 We previously reported that BMSC induce activation and/or increased expression of molecules involved in CLL survival, such as MCL1. 45 This study, however, is the first to systematically analyze GE changes induced by BMSC, and to uncover BMSC-induced TCL1 expression.
We also show here that the BMSC-induced TCL1 upregulation is associated with down-modulation of AP-1 proteins of the FOS/JUN family, which, however, were preserved in TCL1 complexes. JUN, FOS, ATF and MAF protein family members form the dimeric AP-1 complex that differentially regulates GE, depending on the different combinations of heterodimers and the cellular context. 46 AP-1 proteins not only function as oncogenes but also have tumor-suppressive and apoptosis-inducing activity, 24 particularly in lymphoid cells. For example, growth factor withdrawal induces c-JUN and c-FOS in lymphoid cells, accompanied by apoptosis. 47 Moreover, JUNB acts as a negative regulator of B-cell proliferation and transformation. 48 Pekarsky et al. 17 demonstrated that TCL1 physically interacts with c-JUN, JUNB and c-FOS, and inhibits AP-1 transcriptional activity. These findings suggested that TCL1 inhibits and antagonizes AP-1-regulated pro-apoptotic factors that normally control B-cell homeostasis. In the context of these previous findings, our data indicate that BMSC support CLL cell survival by induction of TCL1 and by suppression of FOS and JUN, the latter of which either directly or as a counter-regulatory consequence of the strong TCL1 induction.
Interestingly, TCL1 upregulation by BMSC was in our hands also associated with downregulation of miRNA-29b, miRNA-181b and miRNA34b, which are shown to be negatively TCL1 regulating. 21 The kinetics of this miRNA downregulation in relationship to the sustained, but much earlier initiated TCL1 mRNA and protein induction, indicates that a miRNA-based modulation is only in part responsible for TCL1 upregulation by BMSC. TCL1 targeting miRNAs in this setting may in fact be a fine-tuning mechanism acting in a regulatory fashion in addition to transcriptional activation of CLL cells by BMSC co-culture. With respect to TCL1 regulation, our data overall implicate that complex and concerted transcriptional and post-transcriptional mechanisms, conceivably even affecting AP-1 expression, are involved. Besides identification of the key regulatory molecules included in the observed TCL1 induction, future studies also need to address to which degree the observed miRNA downregulation actually enhances TCL1 levels, and if so, whether preferentially via reduced mRNA degradation or release of the miRNA-based translation arrest. In the need of a better concept of TCL1's regulatory loops, the relevance of such follow-up studies on the mechanisms of environmentally mediated TCL1 modulation is supported by our observation that TCL1 by itself acts as an important sensitizer towards milieuderived signals, especially via the BCR. 19 Novel therapeutic strategies in CLL are developed to disrupt CLL-BMSC interactions, causing mobilization of CLL cells from protective BMSC 'niches' into the blood. Specifically, CXCR4 antagonists are currently introduced into treatment for CLL, multiple myeloma and acute myelogenous leukemia in first clinical trials. 49 Our data in this study provide an additional, novel molecular rationale for such an approach. CLL cells are released and mobilized from BMSC in a CXCR4 antagonist dose-dependent fashion, 50 and thereby consequently become deprived from stroma-derived signals that induce and maintain TCL1 expression. This could re-instate the AP-1-dependent pro-apoptotic machinery. Future clinical trials and correlative studies could be designed to address this important question. Collectively, our data demonstrate that genetic events are not a prerequisite for proto-oncogene activation and that BMSC-derived signals from the microenvironment have an even greater role in the maintenance of the CLL clone than previously thought.
